Registration Dossier

Toxicological information

Repeated dose toxicity: inhalation

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: inhalation
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)

Data source

Reference
Reference Type:
secondary source
Title:
Full Public Report Sodium Ethyl Xanthate Priority Existing Chemical No. 5
Author:
Australian Government Publishing Service Canberra
Year:
1995
Bibliographic source:
Australian Government Publishing Service Canberra

Materials and methods

Test guideline
Qualifier:
equivalent or similar to
Guideline:
OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
GLP compliance:
not specified

Test material

Reference
Name:
Unnamed
Type:
Constituent
Type:
Constituent
Test material form:
aerosol dispenser: not specified
Remarks:
migrated information: aerosol

Test animals

Species:
mouse
Strain:
Swiss Webster
Sex:
male

Administration / exposure

Route of administration:
inhalation: aerosol
Type of inhalation exposure:
whole body
Vehicle:
air
Analytical verification of doses or concentrations:
yes
Duration of treatment / exposure:
30-day
Frequency of treatment:
6 hrs daily, 5 days a week for a total of 20 exposures in 1 month
Doses / concentrationsopen allclose all
Remarks:
Doses / Concentrations:100 mg/m3Basis:nominal conc.
Remarks:
Doses / Concentrations:800 mg/m3Basis:nominal conc.
No. of animals per sex per dose:
10

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
10 from the original group and 5/6 replacement animals died. Convulsions hyperactivity in 5/16 prior to death.
Mortality:
mortality observed, treatment-related
Description (incidence):
10 from the original group and 5/6 replacement animals died. Convulsions hyperactivity in 5/16 prior to death.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
No change
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Description (incidence and severity):
Higher liver to body weight ratio than controls. Higher absolute liver weight
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
No changes

Effect levels

open allclose all
Dose descriptor:
NOAEC
Effect level:
100 mg/m³ air (analytical)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: Higher liver to body weight ratio than controls. No treatment related change
Dose descriptor:
LOAEC
Effect level:
800 mg/m³ air (analytical)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: Higher liver to body weight ratio than controls ratio than controls. Higher absolute liver weight.10 from the original group and 5/6 replacement animals died. Convulsions hyperactivity in 5/16 prior to death.

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Conclusions:
The results of this study indicate that potassium amyl xanthate has an adverse effect on the central nervous system and liver in mice. There were no treatment-related changes in thehaematological or urinalysis values in any of the animals.